Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy

Qu-Lai Tang\(^a\), Li-Xing Gu\(^b\), Yao Xu\(^b\), Xing-Hua Liao\(^b\), Yong Zhou\(^b\), and Tong-Cun Zhang \(^{\circ a}\)

\(^a\)Key Laboratory of Industrial Fermentation Microbiology of the Ministry of Education & Tianjin Key Laboratory of Industrial Microbiology, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China; \(^b\)College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei, China

**ABSTRACT**

As gene delivery tools, lentiviral vectors (LV) have broad applications in chimeric antigen receptor therapy (CAR-T). Large-scale production of functional LV is limited by the adherent, serum-dependent nature of HEK293T cells used in the manufacturing. HEK293T adherent cells were adapted to suspension cells in a serum-free medium to establish large-scale processes for functional LV production in a stirred bioreactor without micro-carriers. The results showed that 293 T suspension was successfully cultivated in F media (293 CD05 medium and SMM293-TII with 1:1 volume ratio), and the cells retained the capacity for LV production. After cultivation in a 5.5 L bioreactor for 4 days, the cells produced 1.5 ± 0.3 × 10^7 TU/mL raw LV, and the lentiviral transduction efficiency was 48.6 ± 2.8% in T Cells. The yield of LV equaled to the previous shake flask. The critical process steps were completed to enable a large-scale LV production process. Besides, a cryopreservation solution was developed to reduce protein involvement, avoid cell grafting and reduce process cost. The process is cost-effective and easy to scale up production, which is expected to be highly competitive.

**ARTICLE HISTORY**

Received 31 March 2021
Revised 12 May 2021
Accepted 13 May 2021

**KEYWORDS**

Functional; lentiviral vectors; HEK293T cells; stirred bioreactors; CAR-T cell therapy

**CONTACT** Yong Zhou zy110cn@126.com College of Life Science and Health, Wuhan University of Science and Technology, No.2 Huangqiahu West Road, Wuhan, Hubei, 430081, China; Tong-Cun Zhang tony@tust.edu.cn College of Biotechnology, Tianjin University of Science and Technology, NO.29, 13th Street, TEDA District, Tianjin 300457, China

Supplemental data for this article can be accessed here.

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Chimeric antigen receptor therapy (CAR-T) is promising immunotherapy that can targeted destroy cancer cells. Presently, CAR-T is being used in clinical practice for blood cancers [1]. The core of CAR-T cells production is the production of LV [2,3]. Therefore, large-scale production and purification of high-titer LV become the key step for mainstream CAR-T cells manufacturers.

The traditional LV production process used adherent 293 T cells cultivated in the medium with serum [4]. However, the serum composition is complex and the batch difference of serum is unpredictable. Also, trypsin, used to process adherent culture, causes cell fragility, leading to partial membrane rupture and reducing the virus titer [5]; Most of the vaccines or LV in stationary culture systems are scaled up via cell factories and flasks, which are labor-intensive and susceptible to contamination [6].

Compared with adherent cells, suspension cells can be cultivated in a serum-free medium, clear and stable, and can thus avoid adverse cell interactions, simplify the upstream process, and achieve large-scale and high-density growth [7]. Ongoing development of serum-free medium cultivation is the current trend of mammalian cell culture technology [8]. The trend significantly improves the transition from laboratory to clinical-grade production. A previous study reported that the 293 T cell had been adapted in serum-free media as suspension cells using sequential adaptation approach [9]. However, using this approach with a long adaptation cycle [10], the proliferation of 293 T suspension cells was slower than original adherent cells, also LV yield. Considering the lentivirus packaging plasmids that are entirely dependent on the host proliferate for replication [11], therefore, it is very important to maintain cell proliferation, enhance its adapted efficiency and improve LV yield.

Stirred bioreactors have been widely used in the biopharmaceutical industry recently [12]. It is noteworthy that most of the 293 T cells are dependent on micro-carriers in the bioreactors [13] or efficient gene editing for virus production [14]. However, the cost of micro-carriers is high, and the process of cell sampling observation, culture, and large-scale production is complicated [15].

Gene editing technology allows gene inactivation [16] and maybe reduced titers [17]. A really suspension cells can grow freely and directly in the bioreactor and the culture environment is uniform, the operation is simple, the automation is feasible, and the pollution rate and costs are both low. At the same time, the cell digestion step is no longer needed, and the cell volume/density ratio is reduced. Suspension cells are easy to scale up to different containers, making automatic culture convenient while markedly reducing human intervention. Therefore, large-scale LV production is a significantly meaningful effort in suspension with stirred bioreactor without micro-carriers or gene editing.

Thus, the high-density culture of 239 T cell suspension in a stirred bioreactor without micro-carriers is a major challenge. Meanwhile, there is no previous research till date in the literature on the use of fast adaptation for really 293 suspension cells. The present study has been designed to adapt 293 T adherent cells during a short duration into suspension cells and maximize the production of functional LV in a 15-L 3-impeller agitating bioreactor. Our work provided a procedural reference for maximizing the large-scale clinical production of functional LV.

**Materials and methods**

**Materials**

Human renal epithelial cell line (293 T) was purchased from American Type Tissue Collection (CRL-3216). DMEM, fetal bovine serum (FBS), 0.25% trypsin-EDTA, and glutamic acid came from Gibco (ThermoFisher Scientific, USA). 293 CD05 medium and OPM-CHO PFF06 medium (supplemented medium) were purchased from Shanghai OPM Biotechnology Co. Ltd. (Shanghai, China), which are serum-free, inorganic salts, amino acids, and vitamins; SMM293-TII was purchased from Sino Biological Inc. (Beijing, China) and is a serum-free medium designed for the cultivation of a mammalian cell type. Polybrene and polyethylenimine (PEI) were purchased from Sigma-Aldrich (St. Louis, MO,
USA), and *Escherichia coli* DH5α was purchased from TIANGEN Biotech Co., Ltd. (Beijing, China). The expression plasmid (PTK-CAR-CD30-GFP), and packaged plasmid (pMDlg-pRRE, pRSV-REV, and pMD2.G) were provided by Wuhan Bio-raid Biotechnology Co., Ltd. (Wuhan, China). Except FBS, all materials were of non-animal origin in this study.

**Cell adaption**

Our serum-free medium without antibiotics, comprised of 293 CD05 medium and SMM293-TII with 1:1 volume ratio, was named F medium (Supplemental material Table S1). Adherent 293 T cells were passaged after 3 days, using 0.25% trypsin-EDTA to detach cells from dishes, and counted by Trypan blue (Gibco) staining [18]. The cell survival rate was more than 90%. Those cells were centrifuged, resuspended with F medium, and inoculated at a density of 4.0 × 10^5 cells/mL into a 20 mL/125 mL triangulation flask for cell adaption (direct method). The cells were cultivated at 37°C and 130 rpm on a shaking incubator (sk-r1807-e, SCTLOGEX, America) with 5% CO₂. Cell morphology without shaking was observed using a bright field microscope and images were captured using a cell phone camera. Afterward, cells with shaking were sampled and counted every generation. The adaption criteria for 293 T suspension cells were the cell density from 4.0 × 10^5 cells/mL to 1.6 × 10^6 cells/mL after 3 days in culture, while cell viability of more than 90% was maintained [9,19].

**Preparation of suspension cell passages and growth curve determination**

Suspension cells meeting indicators were grown for three generations and then cultured for 8 days with cell densities of 1.0 × 10^5 cells/mL (group A), 2.0 × 10^5 cells/mL (group B), and 4.0 × 10^5 cells/mL (group C), respectively. Samples were taken every 12 hours to determine cell density and cell viability. We used a hemocytometer (717,805, Blaubrand, Germany) to record cell density. Cell viability was determined using Trypan blue staining.

**LV packaging verification**

Four *Escherichia coli* DH5α cultures transfected with expressing plasmids and packaged plasmids were incubated overnight while oscillating. Then, the plasmids were extracted with a large plasmid extraction kit (QIAGEN, Germany). The four plasmid packaging systems were used to transfect suspension cells meeting indicators, and transfection was done with a final concentration of 6 µg/mL PEI and 2 µg/mL plasmid DNA (pMD2. G/pRSV-Rev/pRRE/PTK-CAR-CD30-GFP, 3:5:5:10 ratio). On transfection, the cell density was adjusted to 1 × 10^6 cells/mL [20]. The 293 T suspension cells were cultured in shaking flasks and mixed with the 4 plasmids without an exchange medium on the second day. Adherent 293 T cells were packaged lentiviral as previously described [21]. 5 × 10^6 adherent 293 T cells were seeded in a 100 mm dish a day in advance, mixed with the 4 plasmids on the second day, and added 5 mL complete medium on the third day.

After 72 hours, the cells suspension were harvested for ZOE™ Fluorescent Cell Gallery to verify green fluorescent protein expression. Intact cells removed by low-speed centrifugation (300 g for 5 min) and then centrifuged at high-speed centrifugation (3200 g for 30 min) to discard larger particles. 100 µL of the supernatants was used in the HIV p24 Antigen Rapid Test Cassette (Botelong Immunotechnologies Co., Ltd., Suzhou, China) to determine the packaging effect. To begin transduction, we inoculated 6-well plates with adherent 293 T cells at a total number of 5.0 × 10^5 cells followed that with 0–64 µL of viral supernatant and 2 mL of polybrene (4 g/mL). Three days later, GFP was used to detect the viral packaging ability of adapted 293 T suspension cells by flow cytometry (BD Biosciences). Wells with fewer than 1–10% GFP positive cells were chosen to calculate the transduction titer (TU/mL) using the following formula: (total transduced cell number x proportion
of positive cells)/(viral supernatant volume) [22,23].

**Cryopreservation solution selection**

293 T suspension cells can grow and pack LV in serum-free culture. Cryopreservation should be used with a serum-free formula to ensure consistency across the process. Cryopreservation solutionI was 90% v/v FBS plus 10% DMSO, cryopreservation solutionII was 90% v/v human serum albumin (HAS, CSL Behring AG, Switzerland) plus 10% DMSO, cryopreservation solutionIII was 65% v/v F medium plus 10% DMSO and 25% HAS, and cryopreservation solutionIV was 90% v/v F medium plus 10% DMSO. Cells were counted, centrifuged, and discarded the supernatant. Then, the cell was suspended with four cryopreservation solutions, and each in three tubes. The final concentration per cryotube was 1 × 10⁷ cells/mL. The tubes were held at −80°C overnight in a Mr. Frosty apparatus (Thermo Scientific) and then transferred to liquid nitrogen for a month or more [24]. After resuscitation, the effects of these different cryopreservation solutions on cell morphology, viability, and growth were observed by microscope. The best cryopreservation solution was selected and frozen for 293 T suspension cells and a seed bank was established for late verification tests or large-scale production. LV packaging experiment was repeated at least three times using three different batches of the frozen cell.

**Bioreactor cultivation**

We used a 15-L 3-impeller agitating bioreactor (Z4AEZ0015M, Applikon Biotechnology, Netherlands) with a working volume of 5.5 L containing 0.1% (v/v) nonionic surfactant Pluronic F-68 (Sigma-Aldrich), a constant 130 rpm stirring speed, and 50% dissolved oxygen level. Air was applied to the surface while air and CO₂ bubbled up from the bottom. When the dissolved oxygen fell below 50%, oxygen was pumped in from the bottom. To test for aseptic conditions and reactor airtightness, 24 hours before beginning the experiment, we pumped a portion of a fresh medium into the reactor. Once the experiment began, a constant temperature of 37°C, and a pH value of 7.1 were maintained [25]. Both fermentation and transfection conditions were followed the flask shaking system to pack LV in the bioreactor.

Plasmid complex was added at 10% of the working volume when cell density reached a range of 1.0 × 10⁶ cells/mL. After 24 hours post-transfection, 5% of the working volume of supplemented medium was added. The culture supernatants were harvested at 48 hours post-transfection by ultracentrifugation according to the above operation in LV packaging verification and then allowed to infect primary T cells with a multiplicity of transduction (MOI) of 0, 0.2, 2, 20, and 200. The volume of viral supernatant required was calculated according to the formula [26]: MOI = (transduction titer × viral supernatant volume)/cell number. According to previously described methods, the T-cells have acquired from volunteers who participated in this study, agreed and signed Informed Consent and transfected [27]. Three days after transduction, the cells were used for flow cytometry to evaluate the transduction efficiency.

**Statistics**

The data was representative of three independent experiments, and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) was used for statistical analysis. The data was presented as the mean ± standard deviation. The comparison between groups was done by a two-way analysis of variance test followed by Tukey’s test. Values less than 0.05 were considered to be statistically significant and p values <0.05 or <0.01 were indicated by * or **, respectively.

**Results**

To establish large-scale processes for functional LV production in a stirred bioreactor without micro-carriers, we adapted HEK293T adherent cells to suspension cells in a serum-free medium, plotted with the growth curve, and validated the virus packaging abilities. Eventually, the cells were stored in an effective solution and applied to a bioreactor for LV production.
Figure 1. 293 T suspension cells grown in shake flasks in F medium during cell adaptation. (a) the percentage of cell growth and viability. (b) cell morphology without shaking was observed using a 100× bright field microscope and images were captured using a cell phone camera.

Figure 2. Growth results over 8 d of adapted suspension 293 T cells with cell densities of 1.0 × 10^5 cells/mL (group A), 2.0 × 10^5 cells/mL (group B), and 4.0 × 10^5 cells/mL (group C), respectively. (a) live cell growth curve; (b) cell viability percentages. data are means (SD) of 3 experiments.
**Adherent cell cultivation in serum-free medium**

Figure 1a shows that after 12 subcultures, cell viability of more than 90% was maintained, while adaption cell density expanded from $4.0 \times 10^5$ cells/mL to $1.7 \pm 0.4 \times 10^6$–$4.7 \pm 0.5 \times 10^6$ cells/mL after 3 days in culture except for the first passages. The second adapted generation of 293 T suspension cells had a relatively high rate of cell aggregation (Figure 1b). After two passages, the cells were single-celled or formed chains with...

**Figure 3. Verification of virus packaging capability of 293 T suspension cells.** (a) observation of GFP expression in 293 T suspension cells after infection using 100 μm for green field microscopy. (b) 100 μL cell supernatant was collected, treated at 72 h post-transduction, and tested using an HIV p24 Antigen Rapid Test Cassette. The test shows positive results (2 horizontal lines). (c, d) inoculated 293 T cells with 6 increasing amounts (0–64 μL) of the supernatant were detected using a flow cytometer.

**Figure 4. Effect of thawing on 293 T suspension cells.** (a) Viabilities and densities of 293 T suspension cells grown after freezing in 4 solutions at the first passage and then thawing. ***P < 0.01. (b) the titer of the resuscitated adherent and suspension 293 T cells packing the LV. data are means (SD) of 3 experiments.
uniform size and brightness. Suspension 293 T cells in F medium mostly remained single, with aggregates of up to 5 cells in Figure 1b.

**Effect of inoculum size on the growth curve of 293 T suspension cell**

The growth parameters of three different incubated cell concentrations were examined to determine the effect of inoculum size on the growth curve of 293 T suspension cells: 1.0 × 10^5 cells/mL (group A), 2.0 × 10^5 cells/mL (group B), and 4.0 × 10^5 cells/mL (group C). Initially, all groups experienced increasing viable cell density, but group C began decreasing on day 6, and groups A and B began decreasing on day 7 (Figure 2a). The percentage of cell viability was consistent, and group C had relatively little influence on cell viability in the early stages of culture (Figure 2b). These experimental results demonstrated that the 20 mL F medium met basic nutritional requirements of 293 T suspension cells cultured at high inoculation density (group C) for 6 days.

**Suspension cell virus packaging abilities**

The expression plasmid with GFP was used to verify whether 293 T suspension cells could pack the LV. Fluorescent results in Figure 3a suggested that the cells were able to activate GFP expression. After centrifugation and filtration, the protein card test verified positive results (Figure 3b). The rate of GFP positive cells in infected cells increased in step with the increasing volume of the transfected virus and the virus titer (1.2 × 10^7 TU/mL) was calculated as the GFP positive cells with about 9.6 ± 1.3% conversion (Figure 3c and 3d). These results indicated that when 293 T adherent cells were adapted into suspension cells, and they maintained virus replication ability.

**Cryopreservation solution selection**

When we tested the four cryopreservation solutions for suspended 293 T culture, we found that the cell of solution IV grew from 4.0 ± 0.1 × 10^5 cells/mL to 3.0 ± 0.4 × 10^6 cells/mL cell densities with cell viability of 98.0 ± 2.0%, being the highest values for all 4 solutions after 3 days of cultivation (Figure 4a). Therefore, adding 10% DMSO directly to the culture medium for cryopreservation not only reduced protein involvement and process cost but also aided cryopreservation. Figure 4b and Supplemental material Table S2 show that after cells were resuscitated, the suspension cells still had an average 1.5 ± 0.2 × 10^7 TU/mL virus packaging capability in shake-flasks while adherent cells just had 0.3 ± 0.0 × 10^7 TU/mL virus. This represented a nearly five-fold improvement in virus packaging capability over the original adherent 293 T cells.

**Bioreactor cultivation and LV packaging**

The adapted 293 T cells also need to be proved to suitable for cultivation in the bioreactor. After 2 days of fermentation at a seeding density of 3.8 ± 0.4 × 10^5 cells/mL (130 rpm, 50% OD, pH 7.1, and 37°C), cell viability was greater than 90% and the growth rate had increased to 1.0 ± 0.1 × 10^6 cells/mL, indicating that suspension cells could grow in a bioreactor (Figure 5a). The titer of LV, detected by flow cytometry (Figure 5b) at 72 hours post-transduction of adherent 293 T cells, was about 1.5 ± 0.3 × 10^7 TU/mL. These results showed that cultured suspension cells could grow in the bioreactor and pack LV at a titer similar to that of flask transduction. Low MOI of the unpurified and unconcentrated LV had suffered from very low transduction efficiency to T cells, but transduction efficiency was 48 ± 0.3% (P < 0.01) after MOI = 20 (Figure 5c and 5d).

**Discussion**

Cell adaptation to suspension growth was not always as straightforward and successful as previously described [28]. A stepwise reduction of FBS percentage was performed to adapt serum-free culture conditions, and it usually took at least 4–8 weeks [10,14]. More recent studies have confirmed that specific cell lines may also change their expression of surface receptors during long-term adaptation, which then affects production purposes [29]. Compared to commercially available 293 T suspension cells, the 293 T cell line used in this experiment are from a stable cell source with non-gene editing, convenient for producing biomedical products and clinical applications. 293 T adherent cells successfully were adapted the into suspension cells for about a week in this
study using the commercial serum-free medium 293 CD05 and SMM293-TII.

Our method also has advantages over other adaptation methods, such as easy cultivation, no additional anti-agglomerating agents [30], no need for genetic modification, and micro-carriers to stay uniformly dispersed proliferation. The proposed method saves time, by markedly reducing the introduction of exogenous impurities, being more appropriate for the clinical production of biological products than previously reported adaptation processes. Our adapted cells have passed a sterility test and relevant institutions have identified bacteria. Both seed and a working bank have been established for large-scale production and future utilization.

Lentiviral packaging required 3–5 days [22,23]. The suspension cells with an inoculation density of $4 \times 10^5$ cells/mL resulted in better viability and proliferation and were nutritionally depleted until 6 days. Hence, it could be used as the inoculum cell density. After 3 d of cultivation, cell density had reached at least 3.8 times. Cells could keep their susceptibility and permissiveness to allow efficient virus replication [31]. After multiple passages and cryopreservation recovery, the

Figure 5. Verification of the virus packaging capability of 293 T suspension cells in a 5.5 L working volume bioreactor. (a) the percentage of cell growth curve and viability during fermentation; (b) titer of the 293 T suspension cells packing the LV data are means (SD) of 3 experiments. (c) observation of GFP expression in T cells after transduction using 100 µm for green field microscopy. (d) inoculated T cells at a multiplicity of transduction (MOI) of 0, 0.2, 2, 20, and 200 viruses were detected using a flow cytometer. data are means (SD) of 3 experiments. **P < 0.01, *P < 0.05.
suspension cells had proliferated and maintained their ability to package functional virus. Therefore, we have completed the critical process steps to enable a large-scale and clinical LV production process in a relatively short period.

Suspension cultures are amenable for process automation and easy regulation and control of optimized conditions, resulting in being the current choice for most large-scale bio-manufacturing applications in bioreactor [32]. Today, a variety of stirred-tank bioreactors with well-characterized hydrodynamic properties are available for cell culture [33]. However, the bioreactor demonstrated a deficiency in shear forces and oxygen transfer rates [28]. This study shows that the 15-L and 3-impeller agitating bioreactor can be used to culture human 293 T cells at high-density and package functional LV, which infects T cells without purification and concentration treatments, with excellent results. This was crucial to the feasibility of the product for later optimization.

Suspension cells in a 5.5-L working volume of the bioreactor can be produced about 1.5 ± 0.3 × 10⁷ TU/mL LV stock solution. The production period was just about 4 days. The adapted 293 T suspension cells were successfully cultivated in the bioreactor with a reasonable yield of LV, which means this process can be easily scaled up for industrial production. This yield may not be directly compared between studies because of the difference in transient transfection method, virus determination method, the size of expressed genes, and downstream processing [34,35]. However, as a preliminary study, it has a nearly fivefold improvement in virus packaging capability over the original adherent cells and we believe further improvements of the yield can be made by continuing to optimize the technological process, such as cultivation, transfection, and purification process.

Conclusions

In this study, we established an efficient method with one week of adaption and without the cost of micro-carriers but also has wholly done serum-free process from adaption to cryopreservation, shake flask to scale-up bioreactor as well as the utility of this functional virus, which laid the foundation for further scale-up and eventual industrial application. This study also has significance as a reference for the development of similar 293 T-derived produce in the future and will primarily reduce costs for CAR-T’s clinical and commercial development.

Acknowledgements

This study was supported by grants from the National Key R & D Program of China (2017YFD0400304), the Innovative Research Team of Tianjin Municipal Education Commission (TD13-5015), and the Wuhan Science and Technology Plan Project (2019030703011533).

Author contribution

Yong Zhou, Xing-Hua Liao, Tong-Cun Zhang participated in research design; Qu-Lai Tang and Li-Xing Gu performed the experiments and analyzed the data, and were major contributors in writing the manuscript; Yao Xu provided technical guidance and participated in data acquisition and analysis. All the authors read and approved the final version of the manuscript.

Ethics statement

This study was approved by the Ethics Committee of the affiliated Tianyou Hospital of Wuhan University of Science and Technology.

Disclosure of potential conflicts of interest

No potential conflict of interest was reported by the author(s).

Date availability

The data used to support the findings of this study are available from the corresponding author upon request.

ORCID

Tong-Cun Zhang https://orcid.org/0000-0001-9190-2285

References

[1] Kim DW, Cho JY. Recent advances in allogeneic CAR-T cells. Biomolecules. 2020;10:263.
[2] McCarron A, Donnelley M, McIntyre C, et al. Challenges of up-scaling lentivirus production and processing. J Biotechnol. 2016;240:23–30.
[3] How CW, Ong YS, Low SS, et al. How far have we explored fungi to fight cancer? Semin Cancer Biol. 2021. DOI:10.1016/j.semcancer.2021.03.009
[4] Marin V, Stornaiuolo A, Piovan C, et al. RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope. Mol Ther Methods Clin Dev. 2016;3:16033.

[5] Otsuji TG, Bin J, Yoshimura A, et al. A 3D sphere culture system containing functional polymers for large-scale human pluripotent stem cell production. Stem Cell Reports. 2014;2(5):734–745.

[6] Bora M, Youssuf RW, Dhar P, et al. An overview of process intensification and thermo stabilization for upscaling of Peste des petits ruminants vaccines in view of global control and eradication. Virusdisease. 2018;29(3):285–296.

[7] Sheu J, Beltzer J, Fury B, et al. Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor. Mol Ther Methods Clin Dev. 2015;2:15020.

[8] Nakamura K, Harada Y, Takahashi H, et al. Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for preparing influenza vaccine seed virus. Vaccine. 2019;37:6526–6534.

[9] Beltran Paschoal JF, Patiño SS, Bernardino T, et al. Adaptation to serum-free culture of HEK 293T and Huh7.0 cells. BMC Proc. 2014;8:259.

[10] Lee DK, Park J, Seo DW. Suspension culture of Vero cells for the production of adenovirus type 5. Clin Exp Vaccine Res. 2020;9(1):48–55.

[11] Hegedus A, Kavanagh Williamson M, Khan MB, et al. Evidence for altered glucose metabolism in human immunodeficiency virus type 1 infected primary human CD4(+) T Cells. AIDS Res Hum Retroviruses. 2017;33(12):1236–1247.

[12] Kuystermans D, Avesh M, Al-Rubeai M. Online flow cytometry for monitoring apoptosis in mammalian cell cultures as an application for process analytical technology. Cytotechnology. 2016;68(3):399–408.

[13] Guy HM, McCloskey L, Lye GJ, et al. Characterization of lentiviral vector production using microwell suspension cultures of HEK293T-derived producer cells. Hum Gene Ther Methods. 2013;24(2):125–139.

[14] Bessa MJ, Brandão F, Querido MM, et al. Optimization of the harvesting and freezing conditions of human cell lines for DNA damage analysis by the alkaline comet assay. Mutat Res. 2019;845:402994.

[15] Wu SC, Huang GY, Liu JH. Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. Biotechnol Prog. 2002;18(3):617–622.

[16] Quintana-Bustamante O, Fañanas-Baquero S, Orman I, et al. Gene editing of PKLR gene in human hematopoietic progenitors through s30 and s30 UTR modified TALEN mRNA. PLoS One. 2019;14(10):e0223775.

[17] Choy MM, Sessions OM, Gubler DJ, et al. Production of infectious dengue virus in aedes aegypti is dependent on the ubiquitin proteasome pathway. PLoS Negl Trop Dis. 2015;9(11):e0004227.

[18] Li Y, Li S, Li Y, et al. Generation of a novel HEK293 luciferase reporter cell line by CRISPR/Cas9-mediated site-specific integration in the genome to explore the transcriptional regulation of the PGRN gene. Bioengineered. 2019;10(1):98–107.

[19] Lorenzo E, Méndez L, Rodriguez E, et al. Plasticity of the HEK-293 cells, related to the culture media, as platform to produce a subunit vaccine against classical swine fever virus. AMB Express. 2019;9(1):139.

[20] Morris CD, Azadnia P, De Val N, et al. Differential antibody responses to conserved HIV-1 neutralizing epitopes in the context of multivalent scaffolds and native-like gp140 trimers. mBio. 2017;8(1):8.

[21] Russell TA, Blizinsky KD, Cobia DJ, et al. A sequence variant in human KALRN impairs protein function and coincides with reduced cortical thickness. Nat Commun. 2014;5(1):4858.

[22] Li J, Lam M. Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. e-Life. 2015;e006434.

[23] Yang S, Cao B, Zhou G, et al. Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent Cytotoxicity against non-small cell lung cancer. Front Pharmacol. 2020;11:1089.

[24] Kusena JWT, Shariatzadeh M, Thomas RJ, et al. Understanding cell culture dynamics: a tool for defining protocol parameters for improved processes and efficient manufacturing using human embryonic stem cells. Bioengineered. 2021;12(1):979–996.

[25] Goh JS, Liu Y, Liu H, et al. Highly sialylated recombinant human erythropoietin production in large-scale perfusion bioreactor utilizing CHO-gmt4 (JW152) with restored GnT-I function. Biotechnol J. 2014;9(1):100–109.

[26] Wang L, Wang W, Xu Y, et al. Low levels of SPARC are associated with tumor progression and poor prognosis in Human Endometrial Carcinoma. Onco Targets Ther. 2020;13:11549–11569.

[27] Hsiao F, Frouard J, Gramatica A, et al. Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. PLoS Pathog. 2020;16(4):e1008450.

[28] Gallo-Ramirez LE, Nikolay A, Genzel Y, et al. Bioreactor concepts for cell culture-based viral vaccine production. Expert Rev Vaccines. 2015;14(9):1181–1195.

[29] De Los Milagros Bassani Molinas M, Beer C, Hesse F, et al. Optimizing the transient transfection process of HEK-293 suspension cells for protein production by nucleotide ratio monitoring. Cytotechnology. 2014;66(3):493–514.

[30] Humbert O, Gisch DW, Wohlfahrt ME, et al. Development of third-generation cocal envelope producer cell lines for robust lentiviral gene transfer into Hematopoietic Stem Cells and T-cells. Mol Ther. 2016;24(7):1237–1246.
[31] Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010;51(9):997–1004.

[32] Warnock JN, Al-Rubeai M. Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol Appl Biochem. 2006;45(1):1–12.

[33] Costariol E, Rotondi M, Amini A, et al. Establishing the scalable manufacture of primary human T-cells in an automated stirred-tank bioreactor. Biotechnol Bioeng. 2019;116(10):2488–2502.

[34] Hsu CY, Uludağ H. A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine. Nat Protoc. 2012;7(5):935–945.

[35] Bauler M, Roberts JK, Wu CC, et al. Production of Lentiviral vectors using suspension cells grown in serum-free media. Mol Ther Methods Clin Dev. 2020;17:58–68.